848 related articles for article (PubMed ID: 17261671)
21. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptors and inflammation.
Moraes LA; Piqueras L; Bishop-Bailey D
Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
[TBL] [Abstract][Full Text] [Related]
23. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
24. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
Bełtowski J; Wójcicka G; Jamroz A
Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
[TBL] [Abstract][Full Text] [Related]
25. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptors and the metabolic syndrome.
Bragt MC; Popeijus HE
Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
[TBL] [Abstract][Full Text] [Related]
27. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
28. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
29. The human semaphorin 6B gene is down regulated by PPARs.
Collet P; Domenjoud L; Devignes MD; Murad H; Schohn H; Dauça M
Genomics; 2004 Jun; 83(6):1141-50. PubMed ID: 15177567
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review).
Moore-Carrasco R; Poblete Bustamante M; González Guerra O; Leiva Madariaga E; Mujica Escudero V; Aranguez Arellano C; Palomo I
Mol Med Rep; 2008; 1(3):317-24. PubMed ID: 21479412
[TBL] [Abstract][Full Text] [Related]
31. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
Gardner OS; Dewar BJ; Graves LM
Mol Pharmacol; 2005 Oct; 68(4):933-41. PubMed ID: 16020742
[TBL] [Abstract][Full Text] [Related]
32. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.
Bionaz M; Baumrucker CR; Shirk E; Vanden Heuvel JP; Block E; Varga GA
J Dairy Sci; 2008 Jul; 91(7):2808-13. PubMed ID: 18565938
[TBL] [Abstract][Full Text] [Related]
33. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials.
Arck P; Toth B; Pestka A; Jeschke U
Biol Reprod; 2010 Aug; 83(2):168-76. PubMed ID: 20427759
[TBL] [Abstract][Full Text] [Related]
34. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
Rosenson RS
Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
[TBL] [Abstract][Full Text] [Related]
35. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
37. An overview on biological mechanisms of PPARs.
Kota BP; Huang TH; Roufogalis BD
Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253
[TBL] [Abstract][Full Text] [Related]
38. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Chinetti-Gbaguidi G; Staels B
Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
[TBL] [Abstract][Full Text] [Related]
39. PPAR alpha, fibrates, lipid metabolism and inflammation.
Duval C; Fruchart JC; Staels B
Arch Mal Coeur Vaiss; 2004 Jun; 97(6):665-72. PubMed ID: 15283041
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated changes.
Holdsworth-Carson SJ; Permezel M; Riley C; Rice GE; Lappas M
Placenta; 2009 Feb; 30(2):176-86. PubMed ID: 19070893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
